 1987, 1996, 1999, 2002, 2004. 10 
MODEL DESIGN
A cohort life-table analysis was developed to model life-years (LYs) and quality-adjusted life-years (QALYs) of chocolate consumption vs non-consumption over a lifetime horizon in US adults • Age-and sex-specific disease incidence and mortality rates in the published literature were used to model outcomes of cardiometabolic diseases, including coronary heart disease, stroke, and diabetes • Relative risks of cardiometabolic disease associated with chocolate consumption were obtained from meta-analysis of prospective cohort and cross-sectional studies and applied to estimate the reduction in disease incidence, mortality, and costs associated with chocolate consumption • Utility weights, baseline healthcare costs, and attributable disease costs were obtained from the literature • Costs of chocolate were estimated based on consumption of three 150 mg chocolate bars per week • Outcomes included undiscounted LYs and discounted costs and QALYs. Incremental analyses, stratified by sex, and probabilistic sensitivity analyses (PSAs) were conducted
METHODS

DISAGGREGATED RESULTS
• Chocolate consumption, compared to none, increased undiscounted LYs by 0.74 and 0.99 years and discounted QALYs by 0.54 and 0.45 years for males and females, respectively • QALYs were higher for chocolate consumers and healthcare costs associated with cardiometabolic disease were lower (Table 2) 
RESULTS
• The sugar and fat content of some types of chocolate may be an important factor on the overall impact that consumption has on cardiometabolic disease • This analysis is based on meta-analyses of cross sectional and cohort studies. The observed association between chocolate consumption and reduced incidence of cardiometabolic disease in these studies may not be causal
LIMITATIONS
POPULATION, MORTALITY, AND DISEASE INCIDENCE
• US population statistics for adults were obtained from the US Census 4
• Age-specific all-cause annual mortality risk and annual mortality rates per 100,000 were obtained from the National Center for Health Statistics 5,6
• Age-specific incidence rates of chronic diseases were obtained from the literature and age-specific mortality rates of chronic diseases were obtained from the National Center for Health Statistics 6
• Mortality associated with modeled cardiometabolic disease was removed from all-cause mortality to avoid double-counting
RELATIVE RISKS OF DISEASE
• A literature review was conducted to identify meta-analyses of observational studies assessing the association between chocolate consumption and disease • The literature review identified a meta-analysis that concluded that chocolate consumption was associated with a reduced risk for cardiometabolic diseases, including coronary heart disease, stroke, and diabetes 3 -Authors performed a systematic literature review of randomized trials and cohort, case-control, and cross sectional studies carried out in human adults in which the association between chocolate consumption and the risk of outcomes related to cardiometabolic disorders were reported -Seven studies were identified met inclusion criteria and were included in the analysis -In consideration of heterogeneity in reported chocolate consumption, relative risks of cardiometabolic diseases were obtained for chocolate consumers compared to non-consumers -Statistical analysis using pooled study-specific estimates in a random effects model found that the highest levels of chocolate consumption were associated with a 37% reduction in cardiovascular disease (relative risk 0.63 [95% confidence interval: 0.44, 0.90]), a 29% reduction in stroke, and a 31% reduction in diabetes compared with the lowest levels
QALYS
• Age-specific QALYs reflecting full health were used for modeled patients without cardiometabolic disease. For patients with chronic disease, QALYs were adjusted based on an annual quality of life (QoL) loss and the median survival from time of diagnosis for each disease state • Average or median survival from time of diagnosis was used to estimate healthcare costs of treating patients with cardiometabolic disease • Female healthcare costs were assumed to be 20% higher than those for males based on an analysis of lifetime healthcare costs 11
• One-year attributable costs of cardiometabolic diseases were obtained from various sources in the literature, with the exception of diabetes, where age-specific annual costs were used ( 
CHOCOLATE CONSUMPTION AND COSTS OF CHOCOLATE
• Consumption was based on the number of 150 mg chocolate bars consumed per week and was assumed to be 3 bars per week, consistent with consumption in the meta-analysis • Costs of chocolate consumption were based on the consumer prices of 1.5 oz chocolate bar costs from common chocolate brands -Low cost was estimated at $0.75 per 1.5 oz bar based on $26.95 cost of 36-pack of Hershey chocolate bars -Moderate cost was estimated at $1.50 per 1.5 oz bar based on $1.50 costs of single Divine chocolate bars -High cost was estimated at $2.92 per 1.5 oz bar based on $70.00 cost of 24-pack of Godiva chocolate bars
MODEL ANALYSES
• Incremental analyses were conducted by consumption, cost, and sex from a US health system perspective • A probabilistic sensitivity analysis (PSA) was conducted by running 1,000 simulations. For the PSA, lognormal distributions were used for relative risks, beta distributions for QoL loss, and normal distributions for costs. Standard errors for the PSA were based on data for the relative risks and chocolate costs, were assumed to be 50% of the base case value for QoL loss (due to the uncertainty), and were assumed to be 5% for the costs of disease
• This analysis, based on recent meta-analyses of epidemiologic studies assessing the effect of chocolate consumption on cardiometabolic disease, found that chocolate likely reduces overall direct healthcare costs in the US • Chocolate consumption may be a cost-effective means to reduce the risk of cardiometabolic disease • Given the limitations of observational study data, further research is warranted to confirm these findings Key: ICER -incremental cost-effectiveness ratio; QALY -quality-adjusted life-year; US -United States.
CONCLUSIONS
INCREMENTAL COST-EFFECTIVENESS RATIOS
• Cardiometabolic disease costs were reduced by $7,763 and $6,318 and total healthcare costs were reduced by $5,660 and $2,717 for males and females, respectively • The incremental costs per QALY for chocolate consumption with moderate-cost chocolate were $1,482 and $8,931 for males and females, respectively (-$4,523 and $1,422 for low-cost chocolate and $12,853 and $23,149 for high-cost chocolate) • In the PSA, moderate-cost chocolate consumption had a 97.8% and 89.9% probability of being cost-effective for males and females, respectively, at a $50,000/QALY threshold
